TMB in NSCLC: A Broken Dream?

被引：41

作者：

Bravaccini, Sara ^{[1
]}

Bronte, Giuseppe ^{[1
]}

Ulivi, Paola ^{[1
]}

机构：

[1] IRCCS Ist Romagnolo Tumori IRST Dino Amadori, I-47014 Meldola, Italy

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2021年 / 22卷 / 12期

关键词：

TMB; NSCLC; immune checkpoint inhibitors; TUMOR MUTATIONAL BURDEN; CELL LUNG-CANCER; GENE PANELS; OPEN-LABEL; DOCETAXEL; NIVOLUMAB; IMMUNOTHERAPY; PEMBROLIZUMAB; ATEZOLIZUMAB; CHEMOTHERAPY;

D O I：

10.3390/ijms22126536

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Although immune checkpoint inhibitors have changed the treatment paradigm of a variety of cancers, including non-small-cell lung cancer, not all patients respond to immunotherapy in the same way. Predictive biomarkers for patient selection are thus needed. Tumor mutation burden (TMB), defined as the total number of somatic/acquired mutations per coding area of a tumor genome (Mut/Mb), has emerged as a potential predictive biomarker of response to immune checkpoint inhibitors. We found that the limited use of TMB in clinical practice is due to the difficulty in its detection and compounded by several different biological, methodological and economic issues. The incorporation of both TMB and PD-L1 expression or other biomarkers into multivariable predictive models could result in greater predictive power.

引用

页数：10

共 46 条

[1] The "cancer immunogram" [J].

Blank, Christian U. ;

Haanen, John B. ;

Ribas, Antoni ;

Schumacher, Ton N. .

SCIENCE, 2016, 352 (6286) :658-660

[2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[3] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[4] What's the best modality for patient selection for predicting response to PD-1/PD-L1 inhibitors? [J].

Bravaccini, Sara ;

Ulivi, Paola .

TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (01) :158-159

[5] Implementing TMB measurement in clinical practice: considerations on assay requirements [J].

Buettner, Reinhard ;

Longshore, John W. ;

Lopez-Rios, Fernando ;

Merkelbach-Bruse, Sabine ;

Normanno, Nicola ;

Rouleau, Etienne ;

Penault-Llorca, Frederique .

ESMO OPEN, 2019, 4 (01)

[6] Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice [J].

Campesato, Luis Felipe ;

Barroso-Sousa, Romualdo ;

Jimenez, Leandro ;

Correa, Bruna R. ;

Sabbaga, Jorge ;

Hoff, Paulo M. ;

Reis, Luiz F. L. ;

Galante, Pedro Alexandre F. ;

Camargo, Anamaria A. .

ONCOTARGET, 2015, 6 (33) :34221-34227

[7] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].

Carbone, D. P. ;

Reck, M. ;

Paz-Ares, L. ;

Creelan, B. ;

Horn, L. ;

Steins, M. ;

Felip, E. ;

van den Heuvel, M. M. ;

Ciuleanu, T. -E. ;

Badin, F. ;

Ready, N. ;

Hiltermann, T. J. N. ;

Nair, S. ;

Juergens, R. ;

Peters, S. ;

Minenza, E. ;

Wrangle, J. M. ;

Rodriguez-Abreu, D. ;

Borghaei, H. ;

Blumenschein, G. R. ;

Villaruz, L. C. ;

Havel, L. ;

Krejci, J. ;

Corral Jaime, J. ;

Chang, H. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Chen, A. C. ;

Socinski, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426

[8] Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer [J].

Chae, Young Kwang ;

Viveiros, Pedro ;

Lopes, Gilberto ;

Sukhadia, Bhoomika ;

Sheikh, Muhammad Mubbashir ;

Saravia, Diana ;

Florou, Vaia ;

Sokol, Ethan S. ;

Frampton, Garrett M. ;

Chalmers, Zachary R. ;

Ali, Siraj M. ;

Ross, Jeffrey S. ;

Chang, Sangmin ;

Wang, Si ;

Chiec, Lauren ;

Rahbari, Ashkon ;

Mohindra, Nisha ;

Villaflor, Victoria ;

Shin, Sang Ha ;

Oh, Michael ;

Anker, Jonathan ;

Park, Lee Chun ;

Wang, Victor ;

Chuang, Jeffrey ;

Park, Wungki .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) :1807-1817

[9]

D'Arcangelo Manolo, 2019, Oncotarget, V10, P561, DOI 10.18632/oncotarget.26529

[10] BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors [J].

Dudnik, Elizabeth ;

Peled, Nir ;

Nechushtan, Hovav ;

Wollner, Mira ;

Onn, Amir ;

Agbarya, Abed ;

Moskovitz, Mor ;

Keren, Shoshana ;

Popovits-Hadari, Noa ;

Urban, Damien ;

Mishaeli, Moshe ;

Zer, Alona ;

Allen, Aaron M. ;

Rabinovich, Natalie Maimon ;

Rotem, Ofer ;

Kuznetsov, Teodor ;

Shochat, Tzippy ;

Roisman, Laila C. ;

Bar, Jair .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) :1128-1137

← 1 2 3 4 5 →